6358-06-1

Basic information

• Product Name: 2-Chloro-5-aminophenol
• Synonyms: 3-amino-6-chlorophenol;5-amino-2-chloro-pheno;2-CHLORO-5-AMINOPHENOL;5-AMINO-2-CHLOROPHENOL;4-Chloro-3-hydroxyaniline;2-ch1oro-5-aminophenol;5-azanyl-2-chloro-phenol;2-Chloro-5-aminophenol, >=99%
• CAS NO: 6358-06-1
• Molecular Formula: C₆H₆ClNO
• Molecular Weight: 143.57
• Product Categories: Amines;blocks
• Mol File: 6358-06-1.mol
• Article Data: 13

Chemical Properties

• Melting Point: 160 °C
• Boiling Point: 185.5°C (rough estimate)
• Flash Point: 122.4 °C
• Appearance: Gray/Powder
• Density: 1.2028 (rough estimate)
• Vapor Pressure: 0.00247mmHg at 25°C
• Refractive Index: 1.5618 (estimate)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: DMSO, Methanol
• PKA: 8.55±0.10(Predicted)
• Sensitive: Light Sensitive
• CAS DataBase Reference: 2-Chloro-5-aminophenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-aminophenol(6358-06-1)
• EPA Substance Registry System: 2-Chloro-5-aminophenol(6358-06-1)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 24/25
• RTECS: SJ5720000
• HazardClass: 6.1
• Hazardous Substances Data: 6358-06-1(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

5-Amino-2-chlorophenol is used in the synthesis of antimalarial quinolones. Also used in the synthesis of potent anti-HIV agents based upon pyrimidinylphenylamine 1.

InChI:InChI=1/C6H6ClNO/c7-5-2-1-4(8)3-6(5)9/h1-3,9H,8H2

Upstream product

• 97-52-9 2-methoxy-4-nitrophenylamine 
• 13726-14-2 4-chloro-m-anisidine 
• 121-88-0 5-Nitro-2-aminophenol 
• 619-10-3 5-nitro-2-chlorophenol 

Downstream Products

• 1232505-81-5 5-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-4-chloro-2-methyl-aniline 
• 1273549-74-8 2-{2-Chloro-5-[(R)-5-(4-fluoro-phenyl)-5,6-dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-3-ylamino]-4-methyl-phenoxy}-ethanol 
• 1273550-53-0 {5-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-4-chloro-2-methyl-phenyl}-[(R)-5-(4-fluoro-phenyl)-5,6-dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-3-yl]-amine 
• 1273550-44-9 5-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-4-chloro-2-methyl-phenylamine semicarbazide 
• 94011-08-2 4-chloro-3-(prop-2-yn-1-yloxy)aniline 
• 1349821-08-4 4-chloro-3-(2-phenoxyethoxy)phenylamine 
• 1349821-00-6 6-butyl-3-(3,5-dimethylisoxazol-4-yl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 1349820-99-0 6-butyl-3-(4-chloro-2-methylphenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 1349820-97-8 6-butyl-3-(2-fluoro-4-(trifluoromethyl)phenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 1349820-93-4 6-butyl-3-(2,4-dimethylphenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 1349820-87-6 6-butyl-2-methyl-3-(2-methyl-4-(4-(trifluoromethoxy)phenoxy)phenyl)-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 1349820-65-0 3-ethyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 1349821-33-5 N-[4-chloro-3-(2-dimethylaminoethoxy)phenyl]acetamide 
• 1349821-30-2 4-chloro-3-(2-morpholin-4-yl-ethoxy)phenylamine 

Relevant articles and documents

Novel Series of Dihydropyridinone P2X7 Receptor Antagonists

Identification of singleton P2X7 inhibitor 1 from HTS gave a pharmacophore that eventually turned into potential clinical candidates 17 and 19. During development, a number of issues were successfully addressed, such as metabolic stability, plasma stability, GSH adduct formation, and aniline mutagenicity. Thus, careful modification of the molecule, such as conversion of the 1,4-dihydropyridinone to the 1,2-dihydropyridinone system, proper substitution at C-5″, and in some cases addition of fluorine atoms to the aniline ring allowed for the identification of a novel class of potent P2X7 inhibitors suitable for evaluating the role of P2X7 in inflammatory, immune, neurologic, or musculoskeletal disorders.

DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4, R5, Ra and Rb are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.